Fig. 1
From: A phase I trial of LXS196, a protein kinase C (PKC) inhibitor, for metastatic uveal melanoma
Arithmetic mean (SD) concentration-time profiles following administration of LXS196 on cycle 1 day 1 and cycle 1 day 15 following multiple oral doses a LXS196 200–1000 mg QD and b LXS196 200–400 mg BID. BID twice a day, C1D1 cycle 1 day 1, C1D15 cycle 1 day 15, QD once daily, SD standard deviation.
